



## High-Sensitivity Lateral Flow Assays for SARS-CoV-2 and Other Infections Volume II

Guest Editor:

### Dr. Hideya Kawasaki

Institute for NanoSuit Research,  
Preeminent Medical Photonics  
Education & Research Center,  
Hamamatsu University School of  
Medicine, Hamamatsu, Shizuoka,  
Japan

Deadline for manuscript  
submissions:

**closed (31 May 2024)**

### Message from the Guest Editor

Dear Colleagues,

Point-of-care testing (POCT) is applicable to a variety of areas of medicine and can make a significant difference in patient care. Lateral flow assays (LFAs) are critical in POCT. An LFA is a simple-to-use piece of diagnostic equipment that is used to confirm the presence or absence of a target analyte, such as SARS-CoV-2 or other infective agents, biomarkers in humans or animals, or pollutants in drinking water, food, or animal feed; however, its clinical utility has been questioned due to its limited sensitivity. Numerous strategies are used to improve sensitivity and quantitative detection, e.g., employing several visualization methods, using different labeling reporters, and integrating LFAs into other detection methods, resulting in their benefiting from both LFAs and the advantages of integrated detection devices for SARS-CoV-2 or other infections. This Special Issue invites submissions of novel and innovative original studies as well as comprehensive reviews on this topic.

- lateral flow assay
- point-of-care testing
- SARS-CoV-2
- high sensitivity
- detection device
- labeling reporters
- antigens
- pathogens





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)